Home / Health / New Pill Promises Major Weight Loss
New Pill Promises Major Weight Loss
27 Feb
Summary
- Orforglipron pill achieved 8% weight loss vs. 5% for alternatives.
- Daily oral pill offers convenience without food restrictions.
- Drug faces regulatory review; pricing starts at $149.
Eli Lilly's novel oral pill, orforglipron, demonstrated significant weight loss of up to 8% in recent clinical trials, outperforming current oral semaglutide options. This daily pill, taken without dietary restrictions, aims to enhance convenience and accessibility in the growing weight-loss treatment market.
The trial results, published in The Lancet, showed participants lost an average of six to eight percent of their body weight, compared to four to five percent with semaglutide. Orforglipron also showed greater effectiveness in reducing blood sugar levels.
Orforglipron is currently undergoing regulatory review by the U.S. Food and Drug Administration (FDA). If approved, Eli Lilly plans to offer it starting at $149 for the lowest dose for US patients with obesity.
While effective, the pill also presented higher gastrointestinal adverse effects, leading some participants to discontinue treatment. Longer-term safety and sustained effectiveness remain subjects for future study.
